Close Race Over Stem Cell Question
myfoxny.com - New York,NY,USA
... will advance treatment for spinal cord injuries and debilitating conditions such as Parkinson's disease, sickle cell anemia and multiple sclerosis. ...
See all stories on this topic

Voters asked to approve $450 million for stem cell work
Newsday - Long Island,NY,USA
... as spinal cord injuries, Parkinson's disease, sickle cell anemia and multiple sclerosis and attract leading scientists and research firms to the state. ...
See all stories on this topic

Embryonic Stem Cells and 'MS' don't Mix
American Daily - Stow,OH,USA
By Kevin Roeten (11/06/07) A recent conference call with the 'MS'(Multiple Sclerosis) society, hundreds of callers, two 'MS' hosts, and a moderator, ...
See all stories on this topic

Sangamo BioSciences Announces Presentation of Phase 1b ZFP ...
CNNMoney.com - USA
Additional data were presented suggesting that a single treatment with SB- 509 may increase the mobilization of stem cells into a subject's blood. ...
See all stories on this topic

AHA: Doctors Urged to Attack Obesity as a Disease State
MedPage Today - Little Falls,NJ,USA
... he said that they work in the brain to reduce food intake, in adipose tissue to increase adiponectin and to reduce lipogenesis, in muscles to improve ...
See all stories on this topic

MS Society Event Highlights Childhood MS, UK
The MS Society will shine the spotlight on multiple sclerosis (MS) in children this week when it brings together professionals in paediatric MS and affected families to a groundbreaking event in London on 7 November.06 Nov 2007
Oral Medicine To Be Tested in Philadelphia and Hershey
Enrollment has begun for two large-scale clinical trials testing the
safety and effectiveness of an oral drug in people with relapsing-
remitting MS.
The experimental Biogen-Idec therapy, dimethyl fumarate, or BG00012,
is thought to inhibit the overactive immune response seen in people
with MS. In a Phase II clinical trial, patients taking high doses of
BG00012 had a 69% reduction in active inflammation on MRI scans during
the course of the 24-week study.
Researchers will be conducting clinical trials at sites around the
country, including in Philadelphia and Hershey.

Millennium Pharma says antibody meets main goal
Reuters - USA
The company said the product, MLN1202, reduced a protein that marks the risk of atherosclerotic cardiovascular disease. (Reporting by Sayantani Ghosh in ...
See all stories on this topic

Market Report -- In Play (MLNM)
MSN Money - USA
Millennium Pharm announces MLN1202 significantly reduced marker of systemic inflammation and identifies genomic biomarker for responders Co announces ...
See all stories on this topic

Millennium Announces MLN1202 Significantly Reduced Marker of ...
CNNMoney.com - USA
6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that MLN1202, a novel, humanized monoclonal antibody met its primary endpoint ...
See all stories on this topic

<>MS Society Event Highlights Childhood MS, UK
Medical News Today Tue, 06 Nov 2007 6:20 AM PST
The MS Society will shine the spotlight on multiple sclerosis (MS) in children this week when it brings together professionals in paediatric MS and affected families to a groundbreaking event in London on 7 November.Awareness of MS in children - who have been known to show symptoms at just 13 months old - is very low and the lack of a proper diagnosis may lead to poor care. [click link for full ...</>

Acorda Therapeutics Q3 2007 Earnings Call Transcript
Seeking Alpha - New York,NY,USA
Today, I'm going to provide you with updates on our Fampridine-SR clinical program and our Zanaflex capsules business, as well as, corporate update and then ...
See all stories on this topic

Event Brief of Q3 2007 Teva Pharmaceutical Earnings Conference ...
Insurance News Net (press release) - Harrisburg,PA,USA
Co. has just screened its first patient in the course of two Phase III clinical trials for oral MS candidates Laquinimod. 3. ...
See all stories on this topic